Effect of ramucirumab on progression free survival and quality of life in conventional drug resistant or metastatic non-squamous variant of non-small cell lung cancers: a pilot study

Neelam Kumari; Rambit Chandra Dwivedi; Krishna Kant Singh; Shailendra Kumar Yadav; Dharmendra Kumar; Dhirendra Pratap Singh

doi:10.18203/2349-2902.isj20250144

Authors

Neelam Kumari Department of General Surgery, KGMU, Lucknow, UP, India
Rambit Chandra Dwivedi Department of General Surgery, KGMU, Lucknow, UP, India
Krishna Kant Singh Department of General Surgery, KGMU, Lucknow, UP, India
Shailendra Kumar Yadav Department of General Surgery, KGMU, Lucknow, UP, India
Dharmendra Kumar Department of Anaesthesia and Critical Care, S. N. Medical College, Agra, UP, India
Dhirendra Pratap Singh Department of General Surgery, KGMU, Lucknow, UP, India

DOI:

https://doi.org/10.18203/2349-2902.isj20250144

Keywords:

NSCLC, Ramucirumab, Lung cancer

Abstract

Background: Lung cancer is the leading cause of cancer-related death in India overall with the lowest five-year survival rate. Early detection of lung cancer is challenging due to the absence of usual clinical signs.

Methods: This non-randomised, single-arm, retrospective and prospective, pilot observational study enrolled 20 adult patients who have histologically or cytologically confirmed metastatic/drug-resistant/relapsed non-squamous NSCLC, having measurable disease at the time of study entry as defined by the response evaluation criteria in solid tumours (RECIST) with an Eastern cooperative oncology group (ECOG) performance status score of 0 to 2 and adequate organ function are eligible to participate in the study.

Results: The survival rate is exceedingly poor in the case of metastatic non-small cell lung cancer. The primary mass shrunk in size as the sum of the largest diameters (SLD) fell by a modest 12.22% up to the third chemotherapy cycle and a further 9.78% up to the sixth chemotherapy cycle. The progression-free survival duration was found 250.82 days, or roughly 8.33 months, and the overall survival (OS) period was 459 days, or approximately 15.3 months. Overall, the mean trial outcome index increased by 9.31% with additional chemotherapy cycles, while FACT-L increased by a comparable 24.25 percent.

Conclusions: Angiogenesis inhibitors, due to their novel mechanism of action, provide new therapeutic options for metastatic NSCLC. Despite our inability to draw statistically significant conclusions from these encouraging data, our experience with ramucirumab has been truly pleasant thus far.

Metrics

Metrics Loading ...

Author Biography

Krishna Kant Singh, Department of General Surgery, KGMU, Lucknow, UP, India

Department of Surgery, Assistant Professor

References

Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. In Mayo clinic proceedings 2008;83(5):584-94. DOI: https://doi.org/10.4065/83.5.584

Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA: a cancer journal for clinicians. 2019;69(1):7-34. DOI: https://doi.org/10.3322/caac.21551

Spiro SG, Silvestri GA. One hundred years of lung cancer. Am J Respiratory Crit Care Med. 2005;172(5):523-9. DOI: https://doi.org/10.1164/rccm.200504-531OE

Lee SH. Chemotherapy for lung cancer in the era of personalized medicine. Tuberculosis and respiratory diseases. 2019;82(3):179-89. DOI: https://doi.org/10.4046/trd.2018.0068

Doebele RC, Spigel D, Tehfe M, Thomas S, Reck M, Verma S, et al. Phase 2, randomized, open‐label study of ramucirumab in combination with first‐line pemetrexed and platinum chemotherapy in patients with nonsquamous, advanced/metastatic non-small cell lung cancer. Cancer. 2015;121(6):883-92. DOI: https://doi.org/10.1002/cncr.29132

Jemal A, Siegel R, Ward E, Yongping H, Jiaquan X, Taylor M, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71-96. DOI: https://doi.org/10.3322/CA.2007.0010

Iuliis FD, Vendittozzi S, Taglieri L, Salerno G, Lanza R, Scarpa S. Metronomic chemotherapy preserves quality of life ensuring efficacy in elderly advanced non small cell lung cancer patients. Int J Cancer Clin Res. 2016;3:46 DOI: https://doi.org/10.23937/2378-3419/3/2/1046

Gandara DR, Chansky K, Albain KS, Leigh BR, Gaspar LE, Lara Jr PN, et al. Consolidation docetaxel after concurrent chemoradiotherapy in stage IIIB non-small-cell lung cancer: Phase II Southwest Oncology Group Study S9504. J Clin Oncol. 2003;21(10):2004-10. DOI: https://doi.org/10.1200/JCO.2003.04.197

Yoon HH, Bendell JC, Braiteh FS, Firdaus I, Philip PA, Cohn AL, et al. Ramucirumab (RAM) plus FOLFOX as front-line therapy (Rx) for advanced gastric or esophageal adenocarcinoma (GE-AC): Randomized, double-blind multicenter phase 2 trial. J Clin Oncol. 2014:32(15):4004. DOI: https://doi.org/10.1200/jco.2014.32.15_suppl.4004

Hong S, Tan M, Wang S, Luo S, Chen Y, Zhang L. Efficacy and safety of angiogenesis inhibitors in advanced non-small cell lung cancer: a systematic review and meta-analysis. J Cancer Res Clin Oncol. 2015;141(5):909-21. DOI: https://doi.org/10.1007/s00432-014-1862-5

Buccheri G, Ferrigno D, Tamburini M. Karnofsky and ECOG performance status scoring in lung cancer: a prospective, longitudinal study of 536 patients from a single institution. Europ J Cancer. 1996;32(7):1135-41. DOI: https://doi.org/10.1016/0959-8049(95)00664-8

Greer JA, Pirl WF, Jackson VA, Muzikansky A, Lennes IT, Gallagher ER, et al. Perceptions of health status and survival in patients with metastatic lung cancer. J Pain Symptom Management. 2014;48(4):548-57 DOI: https://doi.org/10.1016/j.jpainsymman.2013.10.016

Beckles MA, Spiro SG, Colice GL, Rudd RM. Initial evaluation of the patient with lung cancer: symptoms, signs, laboratory tests, and paraneoplastic syndromes. Chest. 2003;123(1):97S-104S. DOI: https://doi.org/10.1378/chest.123.1_suppl.97S

Das M, Wakelee H. Angiogenesis and lung cancer: ramucirumab prolongs survival in 2nd-line metastatic NSCLC. Translational Lung Cancer Res. 2014;3(6):397.

Camidge DR, Berge EM, Doebele RC, Ballas MS, Jahan T, Haigentz Jr M, et al. A phase II, open-label study of ramucirumab in combination with paclitaxel and carboplatin as first-line therapy in patients with stage IIIB/IV non-small-cell lung cancer. J Thoracic Oncol. 2014;9(10):1532-9.

Eser S, Göksel T, Erbaycu AE, Baydur H, Başarık B, Yanık AÖ, et al. Comparison of generic and lung er-specific quality of life instruments for predictive ability of survival in cancer-patients with advanced lung cancer. SpringerPlus. 2016;5(1):1-1. DOI: https://doi.org/10.1186/s40064-016-3492-7

Camidge DR, Berge EM, Doebele RC, Ballas MS, Jahan T, Haigentz Jr M, et al. Phase II, open- label study of ramucirumab in combination with paclitaxel and carboplatin as first-line therapy in patients with stage IIIb/IV non-smaller lung cancer. J Thoracic Oncol. 2014:9(10):1532-9. DOI: https://doi.org/10.1097/JTO.0000000000000273

Perol M, Ciuleanu TE, Arrieta O, Prabhas K, Syrigos KN, Goksel T, et al. Quality of life results from the phase 3 REVEL randomized clinical trial of ramucirumab -plus-docetaxel versus placebo-plus-docetaxel in advanced/metastatic non-small cell lung cancer patients with progression after platinum based chemo therapy. Lung Cancer. 2016;93:95-103. DOI: https://doi.org/10.1016/j.lungcan.2016.01.007